Manatt Health Partner Rachel Sher will speak in a session titled “The FDCA Impact of Dobbs” at the 2022 Enforcement, Litigation, and Compliance Conference: For the Drug, Device, Food, and Tobacco Industries hosted by the Food and Drug Law Institute (FDLI) on December 7.

The session will dive into what impacts may come from overturning the federal precedents found in Roe v. Wade and Casey v. Planned Parenthood in connection to FDA-regulated companies. The session will cover whether states can prevent companies from selling drugs approved by the FDA, the implications for conducting sponsored clinical trials with pregnant patients, data privacy concerns, the implications for digital health apps regulated by the FDA, and obligations and pitfalls for enforcement, especially concerning state-level enforcement and conflicts with FDA jurisdiction.

The 2022 FDLI Enforcement, Litigation, and Compliance Conference brings together industry, regulators, attorneys, litigators, academics and consultants to discuss trends and issues in enforcement and compliance, the latest developments in both civil and criminal litigation, and recent cases and settlements. This year’s conference will offer an opportunity to hear from and interact with top officials from the FDA, DOJ, FTC and other government agencies. The conference will focus on bringing the conversation to staying compliant and inspection ready as the FDA ramps back up inspections, what companies need to do to plan for and manage enforcement risk, trends in criminal and civil litigation, and government priorities for the new year.

As a special offer, FDLI is offering 15% off registration for this session with the discount code SAVE15.

To learn more and register, click here.